| References: |
BP-1-102 is a potent, orally bioavailable and selective STAT3 inhibitor. BP-1-102 binds Stat3 with an affinity (K(D)) of 504 nM, blocks Stat3-phospho-tyrosine (pTyr) peptide interactions and Stat3 activation at 4-6.8 μM, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells. BP-1-102-mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Krüppel-like factor 8, which is identified as a Stat3 target gene that promotes Stat3-mediated breast tumor cell migration and invasion. For the detailed information of STAT3 Inhibitor XVIII, BP-1-102, the solubility of STAT3 Inhibitor XVIII, BP-1-102 in water, the solubility of STAT3 Inhibitor XVIII, BP-1-102 in DMSO, the solubility of STAT3 Inhibitor XVIII, BP-1-102 in PBS buffer, the animal experiment (test) of STAT3 Inhibitor XVIII, BP-1-102, the cell expriment (test) of STAT3 Inhibitor XVIII, BP-1-102, the in vivo, in vitro and clinical trial test of STAT3 Inhibitor XVIII, BP-1-102, the EC50, IC50,and affinity,of STAT3 Inhibitor XVIII, BP-1-102, Please contact DC Chemicals. |
